Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy

Author(s): Yan-Bei Ren, Shang-Jun Sun, Shuang-Yin Han*

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 1 , 2018

Become EABM
Become Reviewer
Call for Editor


T-cell therapy using genetically engineered T cells modified with either T cell receptor or chimeric antigen receptor holds great promise for cancer immunotherapy. The concerns about its toxicities still remain despite recent successes in clinical trials. Temporal and spatial control of the engineered therapeutic T cells may improve the safety profile of these treatment regimens. To achieve these goals, numerous approaches have been tested and utilized including the incorporation of a suicide gene, the switch-mediated activation, the combinatorial antigen recognition, etc. This review will summarize the toxicities caused by engineered T cells and novel strategies to overcome them.

Keywords: Immunotherapy, Genetically engineered T cells, Chimeric antigen receptor, Gene therapy, T-cell therapy, suicide gene.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 22 March, 2018
Page: [78 - 83]
Pages: 6
DOI: 10.2174/1381612824666171227222624

Article Metrics

PDF: 42
HTML: 10
PRC: 1